- Home
- DNA vs IMNM Comparison
DNA vs IMNM Comparison
Compare DNA & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNA
- IMNM
- Stock Information
- Founded
- DNA 2008
- IMNM 2006
- Country
- DNA United States
- IMNM United States
- Employees
- DNA N/A
- IMNM N/A
- Industry
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- DNA Health Care
- IMNM Health Care
- Exchange
- DNA Nasdaq
- IMNM Nasdaq
- Market Cap
- DNA 562.1M
- IMNM 806.1M
- IPO Year
- DNA N/A
- IMNM 2020
- Fundamental
- Price
- DNA $6.46
- IMNM $8.93
- Analyst Decision
- DNA Sell
- IMNM Strong Buy
- Analyst Count
- DNA 5
- IMNM 5
- Target Price
- DNA $17.25
- IMNM $28.60
- AVG Volume (30 Days)
- DNA 2.0M
- IMNM 676.2K
- Earning Date
- DNA 05-08-2025
- IMNM 03-27-2025
- Dividend Yield
- DNA N/A
- IMNM N/A
- EPS Growth
- DNA N/A
- IMNM N/A
- EPS
- DNA N/A
- IMNM N/A
- Revenue
- DNA $227,043,000.00
- IMNM $10,129,000.00
- Revenue This Year
- DNA N/A
- IMNM N/A
- Revenue Next Year
- DNA $19.36
- IMNM N/A
- P/E Ratio
- DNA N/A
- IMNM N/A
- Revenue Growth
- DNA N/A
- IMNM N/A
- 52 Week Low
- DNA $5.26
- IMNM $8.39
- 52 Week High
- DNA $48.00
- IMNM $26.70
- Technical
- Relative Strength Index (RSI)
- DNA 28.50
- IMNM 42.19
- Support Level
- DNA $6.59
- IMNM $8.39
- Resistance Level
- DNA $7.34
- IMNM $9.53
- Average True Range (ATR)
- DNA 0.85
- IMNM 0.69
- MACD
- DNA -0.30
- IMNM -0.01
- Stochastic Oscillator
- DNA 2.63
- IMNM 34.38
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.